JANX · Janux Therapeutics, Inc.
$17.28
-0.24 (-1.37%)
At close · Aug 20
Market Cap
$1.07B
Shares
61.14M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$10M
-5.6%
FY2025
Net Income
-$113.63M
-64.7%
FY2025
Operating Margin
-1576.67%
-643.1pp
FY2025
Diluted EPS
-$1.83
-43%
FY2025
Operating Cash Flow
-$82.24M
-87.7%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| $24M | $10M | $10.59M | $8.08M | $8.61M | $3.64M | $0 | |
| $123.98M | $125.9M | $68.39M | $54.92M | $53.44M | $26.24M | $3.04M | |
| $43.57M | $41.77M | $41.05M | $26.14M | $22.26M | $10.33M | $1.8M | |
| -$143.56M | -$157.67M | -$98.85M | -$72.98M | -$67.09M | -$32.93M | -$4.84M | |
| — | -1576.67% | -933.58% | -902.87% | -779.04% | -905.39% | — | |
| $40.96M | $44.04M | $29.85M | $14.69M | $4.03M | $257K | -$1.94M | |
| — | $0 | $0 | $0 | — | — | — | |
| -$102.59M | -$113.63M | -$68.99M | -$58.29M | -$63.06M | -$32.67M | -$6.78M | |
| — | -1136.25% | -651.62% | -721.18% | -732.22% | -898.32% | — | |
| USD/shares | — | -$1.83 | -$1.28 | -$1.32 | -$1.52 | -$1.39 | — |
| USD/shares | — | -$1.83 | -$1.28 | -$1.32 | -$1.52 | -$1.39 | — |
| shares | — | 61.97M | 53.75M | 44.02M | 41.47M | 23.53M | 233.73K |
| shares | — | 61.97M | 53.75M | 44.02M | 41.47M | 23.53M | 915.15K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 7.03×
EV/EBIT
—
Peer median 21.30×
P/E (TTM)
—
Peer median 16.79×
Peer medians compare against the 300 similar-size Biotechnology companies (of 546 listed).